Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
6Customers
2Debt Items
12Related Chains
Source-Backed Evidence Depth
VYNE Therapeutics Inc. (VYNE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
1Distinct source URLs
6High confidence
0.761Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
VYNE Therapeutics Inc. Suppliers
Ticker
Name
Confidence
Evidence
TAY
TAY
90%
The Company will pay tiered royalties to Tay on net sales of such licensed products by the Company, its affiliates, or sublicensees
CUTIA-THERAPEUTICS-HK-LIMITED
CUTIA-THERAPEUTICS-HK-LIMITED
80%
the license agreement with Cutia Therapeutics (HK) Limited
Reciprocal relationship from DERM graph: er serious labor problems that have materially impeded our business operations. Our human capital management objectives include, as applicable, identifying, r…
Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a…
Reciprocal relationship from FBIO graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from FBIO g…
Reciprocal relationship from DERM graph: er serious labor problems that have materially impeded our business operations. Our human capital management objectives include, as applicable, identifying, r…
Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
perating results by effectively increasing our future tax obligations. Results of Operations Comparison of the Three Months Ended March 31, 2026 and 2025 Three Months Ended March 31, Increase/(Decrea…
FOAMIX-PHARMACEUTICALS-LTD
FOAMIX-PHARMACEUTICALS-LTD
62%
O Pharma A/S ("LEO Pharma"). Formulation and use patents for Finacea foam currently expire in 2027 and 2029, respectively, but may experience an earlier loss of exclusivity due to generic entry. For …
HK-LIMITED
HK-LIMITED
62%
nancial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warran…
VYNE Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
VYNE-DEBT-13485
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2018-12-31.
VYNE-DEBT-13484
Warrants outstanding: 27509
90%
xbrl warrant detail from xbrl 2026-03-31.
VYNE Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for VYNE Therapeutics Inc..
VYNE Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
VYNE-OWNER-ANSON-FUNDS-MANAGEMENT-LP
Anson Funds Management LP
90%
13F overlay lists Anson Funds Management LP as top holder; 46 tracked holders.
VYNE Therapeutics Inc. Extended Supply Chain Network
